Skip to main content
Premium Trial:

Request an Annual Quote

Ambry Genetics Neurodevelopmental Genetic Testing Panel

Ambry Genetics has launched a new suite of five genetic tests for neurodevelopmental conditions:

  • IDNext, a broad panel of 140 genes known to be associated with both syndromic and non-syndromic intellectual disability (ID)
  • AutismFirst, a targeted panel of 16 genes recognized by the American College of Medical Genetics and Genomics as associated with syndromic autism spectrum disorders (ASDs)
  • AutismNext, a broader panel of 48 genes that can cause both syndromic and non-syndromic ASDs
  • Neurodevelopment-Expanded, a broad panel of 196 genes designed for patients who have a combination of ID, ASDs, and epilepsy
  • Rett/AngelmanNext, a panel of 22 genes known to cause symptoms of multiple overlapping neurodevelopmental disorders, including Rett syndrome and Angelman syndrome.
The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.